High concentration of raltegravir in semen of HIV-infected men: Results from a substudy of the EASIER-ANRS 138 trial

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 2, 2010, Pages 937-939

  Barau, Caroline ^a   Delaugerre, Constance ^b   Braun, Joséphine ^c   De Castro, Nathalie ^b   Furlan, Valérie ^a   Charreau, Isabelle ^c   Gérard, Laurence ^b   Lascoux Combe, Caroline ^b   Molina, Jean Michel ^b   Taburet, Anne Marie ^a  

^a BICÊTRE HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; FOSAMPRENAVIR; LAMIVUDINE; LOPINAVIR; RALTEGRAVIR; RNA; STAVUDINE; TENOFOVIR; TIPRANAVIR;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DIFFUSION; DRUG EFFICACY; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPERM;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PYRROLIDINONES; SEMEN;

EID: 75749115111     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01261-09     Document Type: Article

References (23)

1. Cao, Y. J., and C. W. Hendrix. 2008. Male genital tract pharmacology: developments in quantitative methods to better understand a complex peripheral compartment. Clin. Pharmacol. Ther. 83:401-412.
2. Cianfriglia, M., M. L. Dupuis, A. Molinari, A. Verdoliva, R. Costi, C. M. Galluzzo, M. Andreotti, A. Cara, R. Di Santo, and L. Palmisano. 2007. HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein. Retrovirology 4:17.
3. Croxtall, J. D., and S. J. Keam. 2009. Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients. Drugs 69:1059-1075.
4. De Castro, N., J. Braun, I. Charreau, G. Pialoux, L. Cotte, C. Katlama, F. Raffi, L. Weiss, J. L. Meynard, Y. Yazdanpanah, C. Delaugerre, I. Madelaine-Chambrin, J. P. Aboulker, and J. M. Molina. 2009. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. Clin. Infect. Dis. 49:1259-1267.
5. Ghosn, J., M. L. Chaix, G. Peytavin, J. L. Bresson, J. Galimand, P. M. Girard, F. Raffi, I. Cohen-Codar, J. F. Delfraissy, and C. Rouzioux. 2008. Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine. J. Antimicrob. Chemother. 61:1344-1347.
6. Ghosn, J., M. L. Chaix, G. Peytavin, E. Rey, J. L. Bresson, C. Goujard, C. Katlama, J. P. Viard, J. M. Treluyer, and C. Rouzioux. 2004. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS 18:1958-1961.
7. Goldwirt, L., A. Barrail-Tran, A. M. Taburet, and V. Furlan. 2009. Quantification of raltegravir (MK 0518) in human plasma by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. [Epub ahead of print.] doi:10.1016/j.jchromb .2009.10.029.
8. Iwamoto, M., L. A. Wenning, A. S. Petry, M. Laethem, M. De Smet, J. T. Kost, S. A. Merschman, K. M. Strohmaier, S. Ramael, K. C. Lasseter, J. A. Stone, K. M. Gottesdiener, and J. A. Wagner. 2008. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin. Pharmacol. Ther. 83:293-299.
9. Jones, A. E., J. A. Talameh, K. B. Patterson, N. L. Rezk, H. A. Prince, and A. D. M. Kashuba. 2009. First-dose and steady-state pharmacokinetics (PK) of raltegravir (RAL) in the genital tract (GT) of HIV uninfected women, abstr. O-06. Tenth Int. Workshop Clin. Pharmacol. HIV Ther., Amsterdam, The Netherlands, 15 to 17 April 2009.
10. Kashuba, A. D., J. R. Dyer, L. M. Kramer, R. H. Raasch, J. J. Eron, and M. S. Cohen. 1999. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 43:1817-1826.
11. Lennox, J. L., E. DeJesus, A. Lazzarin, R. B. Pollard, J. V. Madruga, D. S. Berger, J. Zhao, X. Xu, A. Williams-Diaz, A. J. Rodgers, R. J. Barnard, M. D. Miller, M. J. DiNubile, B. Y. Nguyen, R. Leavitt, and P. Sklar. 2009. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 374:796-806.
12. Pasquier, C., C. Souyris, N. Moinard, L. Bujan, and J. Izopet. 2006. Validation of an automated real-time PCR protocol for detection and quantitation of HIV and HCV genomes in semen. J. Virol. Methods 137:156-159.
13. Pereira, A. S., L. M. Smeaton, J. G. Gerber, E. P. Acosta, S. Snyder, S. A. Fiscus, R. R. Tidwell, R. M. Gulick, R. L. Murphy, and J. J. Eron, Jr. 2002. The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850). J. Infect. Dis. 186:198-204.
14. Reddy, Y. S., S. K. Gotzkowsky, J. J. Eron, J. Y. Kim, W. D. Fiske, S. A. Fiscus, L. Petch, M. S. Cohen, and A. D. Kashuba. 2002. Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men. J. Infect. Dis. 186:1339- 1343.
15. Reddy, Y. S., A. Kashuba, J. Gerber, and V. Miller. 2003. Roundtable report: importance of antiretroviral drug concentrations in sanctuary sites and viral reservoirs. AIDS Res. Hum. Retrovir. 19:167-176.
16. Saksena, N. K., and S. J. Potter. 2003. Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy. AIDS Rev. 5:3-18.
17. Steigbigel, R. T., D. A. Cooper, P. N. Kumar, J. E. Eron, M. Schechter, M. Markowitz, M. R. Loutfy, J. L. Lennox, J. M. Gatell, J. K. Rockstroh, C. Katlama, P. Yeni, A. Lazzarin, B. Clotet, J. Zhao, J. Chen, D. M. Ryan, R. R. Rhodes, J. A. Killar, L. R. Gilde, K. M. Strohmaier, A. R. Meibohm, M. D. Miller, D. J. Hazuda, M. L. Nessly, M. J. DiNubile, R. D. Isaacs, B. Y. Nguyen, and H. Teppler. 2008. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 359:339-354.
18. Tachet, A., E. Dulioust, D. Salmon, M. De Almeida, S. Rivalland, L. Finkielsztejn, I. Heard, P. Jouannet, D. Sicard, and C. Rouzioux. 1999. Detection and quantification of HIV-1 in semen: identification of a subpopulation of men at high potential risk of viral sexual transmission. AIDS 13:823-831.
19. Taylor, S., D. J. Back, S. M. Drake, J. Workman, H. Reynolds, S. E. Gibbons, D. J. White, and D. Pillay. 2001. Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir. J. Antimicrob. Chemother. 48:351-354.
20. Taylor, S., and A. S. Pereira. 2001. Antiretroviral drug concentrations in semen of HIV-1 infected men. Sex. Transm. Infect. 77:4-11.
21. Taylor, S., R. P. van Heeswijk, R. M. Hoetelmans, J. Workman, S. M. Drake, D. J. White, and D. Pillay. 2000. Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men. AIDS 14:1979-1984.
22. ter Heine, R., C. G. Alderden-Los, H. Rosing, M. J. Hillebrand, E. C. van Gorp, A. D. Huitema, and J. H. Beijnen. 2007. Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 21:2505-2514.
23. van Praag, R. M., G. J. Weverling, P. Portegies, S. Jurriaans, X. J. Zhou, M. L. Turner-Foisy, J. P. Sommadossi, D. M. Burger, J. M. Lange, R. M. Hoetelmans, and J. M. Prins. 2000. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS 14:1187-1194.